Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps
Biologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and novel biologicals are expected to follow. Dupilumab...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2023.2254567 |
| _version_ | 1797683510008348672 |
|---|---|
| author | Lisa P. van der Rijst Annet van Royen-Kerkhof Suzanne G. M. A. Pasmans Renske Schappin Marjolein S. de Bruin-Weller Marlies de Graaf |
| author_facet | Lisa P. van der Rijst Annet van Royen-Kerkhof Suzanne G. M. A. Pasmans Renske Schappin Marjolein S. de Bruin-Weller Marlies de Graaf |
| author_sort | Lisa P. van der Rijst |
| collection | DOAJ |
| description | Biologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and novel biologicals are expected to follow. Dupilumab was the first biological registered for AD in pediatric patients and was recently approved for patients aged six months to five years. Current and emerging biologicals may address the unmet need for effective and safe treatment options for pediatric AD patients, however, little is known about the practical implementation of biologicals in infants and preschoolers (aged <6 years), including the timing of treatment initiation, discontinuation, and long-term administration of the subcutaneous injections. Currently, only a small number of biologicals are approved for the treatment of infants and preschoolers for other inflammatory diseases. Consequently, data on the practical implementation of biological treatment remain scarce. In addition, long-term effects, impact on co-morbidities, and impact on live-accentuated vaccination are still unknown. With the introduction of biologicals for AD from the age of six months, potential challenges within the implementation of biologicals may arise. Therefore, we aim to discuss current practical challenges and knowledge gaps of the treatment with biologicals in infants and preschoolers with AD. |
| first_indexed | 2024-03-12T00:15:29Z |
| format | Article |
| id | doaj.art-ea6573b6f7824f078f432f45ebd3f7c7 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:29Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-ea6573b6f7824f078f432f45ebd3f7c72023-09-15T14:40:44ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532023-12-0134110.1080/09546634.2023.22545672254567Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gapsLisa P. van der Rijst0Annet van Royen-Kerkhof1Suzanne G. M. A. Pasmans2Renske Schappin3Marjolein S. de Bruin-Weller4Marlies de Graaf5Department of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children’s HospitalDepartment of Pediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center UtrechtDepartment of Dermatology, Centre of Pediatric Dermatology, Erasmus MC University Medical Centre Rotterdam-Sophia Children’s HospitalDepartment of Dermatology, Centre of Pediatric Dermatology, Erasmus MC University Medical Centre Rotterdam-Sophia Children’s HospitalDepartment of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center UtrechtDepartment of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children’s HospitalBiologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and novel biologicals are expected to follow. Dupilumab was the first biological registered for AD in pediatric patients and was recently approved for patients aged six months to five years. Current and emerging biologicals may address the unmet need for effective and safe treatment options for pediatric AD patients, however, little is known about the practical implementation of biologicals in infants and preschoolers (aged <6 years), including the timing of treatment initiation, discontinuation, and long-term administration of the subcutaneous injections. Currently, only a small number of biologicals are approved for the treatment of infants and preschoolers for other inflammatory diseases. Consequently, data on the practical implementation of biological treatment remain scarce. In addition, long-term effects, impact on co-morbidities, and impact on live-accentuated vaccination are still unknown. With the introduction of biologicals for AD from the age of six months, potential challenges within the implementation of biologicals may arise. Therefore, we aim to discuss current practical challenges and knowledge gaps of the treatment with biologicals in infants and preschoolers with AD.http://dx.doi.org/10.1080/09546634.2023.2254567atopic dermatitisbiological therapypediatric dermatologyimmunomodulating therapychildren |
| spellingShingle | Lisa P. van der Rijst Annet van Royen-Kerkhof Suzanne G. M. A. Pasmans Renske Schappin Marjolein S. de Bruin-Weller Marlies de Graaf Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps Journal of Dermatological Treatment atopic dermatitis biological therapy pediatric dermatology immunomodulating therapy children |
| title | Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps |
| title_full | Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps |
| title_fullStr | Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps |
| title_full_unstemmed | Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps |
| title_short | Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps |
| title_sort | biologicals for pediatric patients with atopic dermatitis practical challenges and knowledge gaps |
| topic | atopic dermatitis biological therapy pediatric dermatology immunomodulating therapy children |
| url | http://dx.doi.org/10.1080/09546634.2023.2254567 |
| work_keys_str_mv | AT lisapvanderrijst biologicalsforpediatricpatientswithatopicdermatitispracticalchallengesandknowledgegaps AT annetvanroyenkerkhof biologicalsforpediatricpatientswithatopicdermatitispracticalchallengesandknowledgegaps AT suzannegmapasmans biologicalsforpediatricpatientswithatopicdermatitispracticalchallengesandknowledgegaps AT renskeschappin biologicalsforpediatricpatientswithatopicdermatitispracticalchallengesandknowledgegaps AT marjoleinsdebruinweller biologicalsforpediatricpatientswithatopicdermatitispracticalchallengesandknowledgegaps AT marliesdegraaf biologicalsforpediatricpatientswithatopicdermatitispracticalchallengesandknowledgegaps |